<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981041</url>
  </required_header>
  <id_info>
    <org_study_id>EPIDAURUS-2020</org_study_id>
    <nct_id>NCT04981041</nct_id>
  </id_info>
  <brief_title>Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI</brief_title>
  <acronym>EPIDAURUS</acronym>
  <official_title>Escalated Single Platelet Inhibition for One Month Plus Direct Oral Anticoagulation in Patients With Atrial Fibrillation and acUte coRonary Syndrome Undergoing percutaneoUS Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The selection of the optimal antithrombotic therapy in patients with nonvalvular atrial&#xD;
      fibrillation (AF) and acute coronary syndrome (ACS) undergoing percutaneous coronary&#xD;
      intervention (PCI) is challenging. Until recently, triple antithrombotic therapy (TAT)&#xD;
      consisting in Aspirin plus Clopidogrel plus OAC was considered the treatment of choice. While&#xD;
      efficiently preventing ischaemic events, TAT is associated with an increase in bleeding&#xD;
      complications. Therefore, in the past years several randomized controlled trials challenged&#xD;
      TAT by comparing a triple antithrombotic therapy (TAT) regimen based on Vitamin K antagonists&#xD;
      (VKA) to a dual antithrombotic regimen (DAT) based on non-vitamin K antagonist oral&#xD;
      anticoagulants (NOACs) and P2Y12-inhibitors, mainly Clopidogrel in patients with AF&#xD;
      undergoing PCI.&#xD;
&#xD;
      However, approximately 30-40% of patients show low response to Clopidogrel and are not&#xD;
      adequately protected against ischaemic events, in particular when presenting with ACS. This&#xD;
      is supported by a recent meta-analysis reporting that TAT compared to DAT is associated with&#xD;
      lower rates of stent thrombosis within 30 days after PCI. It is therefore reasonable to&#xD;
      assume that a more potent platelet inhibition within the first month after PCI might reduce&#xD;
      the rate of ischaemic complications observed in AF patients undergoing PCI, when receiving&#xD;
      DAT. Moreover, a subsequent de-escalation to a less potent platelet inhibition one month&#xD;
      after PCI might prevent an increase in bleeding complications.&#xD;
&#xD;
      In EPIDAURUS the investigators will therefore test the hypothesis that DAT using NOAC plus an&#xD;
      escalated antiplatelet therapy with a potent P2Y12-inhibitor for one month followed by&#xD;
      Clopidogrel reduces ischaemic events without a relevant increase in bleeding complications in&#xD;
      patients with AF and ACS undergoing PCI compared to standard DAT with NOAC plus Clopidogrel.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major ischaemic events defined as the composite of all-cause mortality, myocardial infarction, definite or probable stent thrombosis, ischaemic stroke and systemic thromboembolism</measure>
    <time_frame>6 weeks</time_frame>
    <description>superiority test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding type 2 or higher according to the Bleeding Academic Research Consortium (BARC) criteria</measure>
    <time_frame>6 weeks</time_frame>
    <description>non-inferiority test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite or probable stent thrombosis</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischaemic stroke</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic thromboembolism</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding type 2 or more according to the Bleeding Academic Research Consortium</measure>
    <time_frame>6 weeks</time_frame>
    <description>superiority testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent revascularization</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned hospitalization due to acute heart failure or acute coronary syndrome</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischaemic stroke</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2334</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Potent P2Y12-Inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel 10mg (5 mg in patients ≥ 75 years old or weighing &lt; 60 kg) q.d. per os or Ticagrelor 90mg bid per os</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75mg q.d. per os</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel or Ticagrelor</intervention_name>
    <description>Escalated antiplatelet therapy with a potent P2Y12- inhibitor for one month in patients with atrial fibrillation and indication for treatment non-vitamin K antagonist oral anticoagulants (NOACs)</description>
    <arm_group_label>Potent P2Y12-Inhibition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel and NOAC</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Atrial fibrillation requiring oral anticoagulation&#xD;
&#xD;
          -  STEMI or NSTEMI (biomarker positive acute coronary syndrome) and successful completion&#xD;
             of PCI (randomization will take place within 24h after successful PCI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic renal insufficiency with glomerular filtration rate &lt; 15 ml/min/1.73m2&#xD;
&#xD;
          -  Previous haemorrhagic stroke&#xD;
&#xD;
          -  Contraindication for P2Y12-inhibitor&#xD;
&#xD;
          -  Indication for oral anticoagulation with Vitamin K antagonists&#xD;
&#xD;
          -  Moderate to severe mitral stenosis or mechanical heart valve&#xD;
&#xD;
          -  Any bleeding BARC type ≥ 2 within the last 4 weeks before index procedure&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Inability to cooperate with the protocol requirements&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Participation in another investigational drug study&#xD;
&#xD;
          -  Previous enrolment in this study&#xD;
&#xD;
          -  For women of childbearing potential no negative pregnancy test and no agree to use a&#xD;
             reliable method of birth control during the study&#xD;
&#xD;
          -  Previous treatment with GP IIb/IIIa inhibitors within the last 12 hours&#xD;
&#xD;
          -  A known genetic disorder involved in the metabolism of the study medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Konstantinos Rizas, MD</last_name>
    <phone>0049</phone>
    <phone_ext>89440073169</phone_ext>
    <email>konstantinos.rizas@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steffen Massberg, MD</last_name>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Konstantinos Rizas</investigator_full_name>
    <investigator_title>PD Dr. med. Konstantinos Rizas, Assistant Professor of Medicine, Co-Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

